Sharecare to Present at 41st Annual J.P. Morgan Healthcare Conference

Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its chairman and CEO, Jeff Arnold, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023 at 5:15 p.m. PST.

A live audio webcast and replay of the event will be available online at https://investors.sharecare.com/news-and-events/events-and-presentations.

About Sharecare

Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Relations:

Jen Martin Hall

jen@sharecare.com

Investor Relations:

Bob East, Westwicke

SharecareIR@westwicke.com

Total
0
Shares
Leave a Reply
Related Posts
Read More

Lingo Signs Distribution Deal with Americomm

Lingo Communications, LLC., ("Lingo") a leading global Cloud/UC communications and managed service provider dedicated to serving the SMB, Carrier and Consumer markets, announced today the signing of a new Master Agent agreement with Americomm, one of the nation's premier master agents for telecom services in the United States.
Read More

BioIQ Launches Telehealth Enabled At-Home Saliva Test Kit for COVID-19 with P23 Labs

BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the availability of an at-home RT-PCR COVID-19 testing solution with fully integrated telehealth support. The test is being offered in partnership with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for home saliva collection in conjunction with telehealth oversight. The partnership enables BioIQ to connect employees, health plan members, and individuals with COVID-19 diagnostic testing under the virtual supervision of a clinician.